Navigation Links
SyntheMed Announces New Management Appointments
Date:10/2/2008

ISELIN, N.J., Oct. 2 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD) announced today that Richard L. Franklin, MD, the company's Chairman, has assumed the newly-created position of Executive Chairman and Gere S. diZerega, MD, one of the company's clinical advisors, has assumed the newly-created position of Medical Director. In these consultancy roles, Dr. Franklin will be primarily involved with strategic planning, external communications and Board leadership whereas Dr. diZerega will focus on clinical and regulatory strategy and product planning. Robert P. Hickey, the company's President & CEO stated, "We are very fortunate that Rick and Gere have agreed to expand their involvement with our company and we look forward to benefiting from their experience and expertise."

About SyntheMed, Inc.

SyntheMed, Inc. is a biomaterials company engaged in the development and commercialization of anti-adhesion products and other surgical implants based on its proprietary bioresorbable polymer technology. The company is developing a portfolio of anti-adhesion products lead by REPEL-CV(R) Adhesion Barrier, an anti-adhesion product intended for use in open heart surgical procedures. REPEL-CV is currently marketed internationally and is awaiting FDA approval to market in the United States.

Statements in this press release that are not statements of historical fact constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include but are not limited to (i) potential adverse developments regarding the company's efforts to obtain and maintain required regulatory approvals; (ii) potential inability to secure funding as and when needed to support the company's future activities and (iii) unanticipated delays associated with manufacturing and marketing activities. Reference is made to the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007 for a description of these, as well as other, risks and uncertainties.


'/>"/>
SOURCE SyntheMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SyntheMed Completes $4.0 Million Equity Placement
2. SyntheMed To Present at the AdvaMed 2008 MedTech Conference
3. SyntheMed to Present at Canaccord Adams Small-Cap Orthopedics Conference
4. SyntheMed Files Universal Shelf Registration
5. SyntheMed to Present at the Acumen BioFin Conference
6. SyntheMed to Host Symposium on Adhesions in Cardiac Surgery
7. Alba Therapeutics Corporation Announces Promotions
8. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
9. 23andMe Announces Breast Cancer Initiative
10. Exiqon A/S Today Announces a Grant of License to Roche Diagnostics
11. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... ... skill-building and compliance training platform on mobile devices, today released a new interactive ... Requirements for Medical Devices. The course is essential for owners or operators of ...
(Date:5/3/2016)... ... May 03, 2016 , ... Flagship Biosciences, the leader in ... its Board of Directors. Dr. Gillett recently retired from Charles River Laboratories (CRL), ... Chief Scientific Officer. A board-certified veterinary pathologist, Dr. Gillett joined Charles River in ...
(Date:5/3/2016)... 2016 - And Other Rising ... of Those Competitor Biologics  - Biosimilar Drug ... Prospects ,  Who are the most important ... are their sales potentials? Discover, in our updated survey, ... opportunities and revenue forecasting. Visiongain,s ...
(Date:5/3/2016)... ... May 03, 2016 , ... Nashville Fertility Center ... A contingency of reproductive endocrinologists, including Dr. George Hill at Nashville ... to help them build families. , Ovation Fertility is a nationwide network of ...
Breaking Biology Technology:
(Date:3/17/2016)... , March 17, 2016 ABI ... intelligence, forecasts the global biometrics market will reach ... impressive 118% increase from 2015. Consumer electronics, particularly ... embedded fingerprint sensors anticipated to reach two billion ... Dimitrios Pavlakis , Research Analyst at ...
(Date:3/11/2016)... 11, 2016 http://www.apimages.com ) - --> ... is available at AP Images ( http://www.apimages.com ) - ... used to produce the new refugee identity cards. DERMALOG will be ... CeBIT in Hanover next week.   --> ... be used to produce the new refugee identity cards. DERMALOG will ...
(Date:3/9/2016)... , March 9, 2016 ... identified that more than 23,000 public service employees either ... been receiving their salary unlawfully.    --> ... government identified that more than 23,000 public service employees ... had been receiving their salary unlawfully.    --> ...
Breaking Biology News(10 mins):